Sanchorawala, V. Palladini, G. Minnema, M.C. Jaccard, A. Lee, H.C. Gibbs, S. Mollee, P. Venner, C. Lu, J. Schönland, S. Gatt, M. Suzuki, K. Kim, K. Cibeira, M.T. Beksac, M. Libby, E. Valent, J. Hungria, V. Wong, S.W. Rosenzweig, M. Bumma, N. Chauveau, D. Gries, K.S. Fastenau, J. Tran, N.P. Qin, X. Vasey, S.Y. Weiss, B.M. Vermeulen, J. Ho, K.F. Merlini, G. Comenzo, R.L. Kastritis, E. Wechalekar, A.D., Health-related quality of life in patients with light chain amyloidosis treated with bortezomib, cyclophosphamide, and dexamethasone ± daratumumab: Results from the ANDROMEDA study, American Journal of Hematology, (97), 719-730, 2022, John Wiley and Sons Inc, 0361-8609, 1096-8652